Helicobacter pylori treatment in Turkey : Current status and rational treatment options
Copyright: © 2020 by Istanbul Northern Anatolian Association of Public Hospitals..
According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, many countries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1 gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however, current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence, cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs to revise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori. This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations for rational therapeutic considerations for the eradication of the bacterium.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Northern clinics of Istanbul - 7(2020), 1 vom: 01., Seite 87-94 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kaplan, Mustafa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Eradication |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.14744/nci.2019.62558 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308178386 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308178386 | ||
| 003 | DE-627 | ||
| 005 | 20231225131201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.14744/nci.2019.62558 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1027.xml |
| 035 | |a (DE-627)NLM308178386 | ||
| 035 | |a (NLM)32232212 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kaplan, Mustafa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Helicobacter pylori treatment in Turkey |b Current status and rational treatment options |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2020 by Istanbul Northern Anatolian Association of Public Hospitals. | ||
| 520 | |a According to the TURHEP study, the prevalence of Helicobacter pylori in Turkey is 82.5%. After FDA approval in 1995, many countries have used standard triple therapy (proton pump inhibitor 40 mg b.i.d clarithromycin 500 mg b.i.d and amoxicillin 1 gr b.i.d) for Helicobacter pylori treatment. In the beginning, eradication rates were above 90% in many countries; however, current studies have demonstrated a prominent decrease in successful treatment rates, even down to 60%. This unfavorable reduction stimulated searches for new treatment protocols. Treatment protocols differ according to country, prevalence, cost-effectiveness, antibiotic resistance, CYP2C19 polymorphism and eradication rates. Thus, each country/region needs to revise its own therapeutic results and the efficacy of various eradication regimens in the treatment of Helicobacter pylori. This report aims to review the current status of Helicobacter pylori treatment in Turkey and to provide recommendations for rational therapeutic considerations for the eradication of the bacterium | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Eradication | |
| 650 | 4 | |a Helicobacter pylori | |
| 650 | 4 | |a Turkey | |
| 650 | 4 | |a proton pump inhibitors | |
| 700 | 1 | |a Tanoglu, Alpaslan |e verfasserin |4 aut | |
| 700 | 1 | |a Duzenli, Tolga |e verfasserin |4 aut | |
| 700 | 1 | |a Tozun, Ayse Nurdan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Northern clinics of Istanbul |d 2014 |g 7(2020), 1 vom: 01., Seite 87-94 |w (DE-627)NLM267731132 |x 2536-4553 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2020 |g number:1 |g day:01 |g pages:87-94 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.14744/nci.2019.62558 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2020 |e 1 |b 01 |h 87-94 | ||